
Paula Radcliffe's teen daughter's two cancer symptoms before diagnosis
Paula Radcliffe's teenage daughter showed two warning signs before her cancer diagnosis. British running icon Paula Radcliffe's 18-year-old daughter, Isla Lough, was faced with battling a rare ovarian cancer which was detected during the Covid-19 lockdown five years ago.
Isla's health cancer journey began when she started to experience stomach pains and a shortness of breath. Months prior to this, Paula had noticed earlier subtle indicators that Isla wasn't well, which included bladder issues and unusual bleeding outside her regular periods.
Concerned for her daughter's health, Paula arranged for a paediatrician consultation, leading to hospital scans in Nice, where their worst fears were confirmed. A week later, Isla was in hospital commencing her first round of chemotherapy treatments, Surrey Live reports.
Diagnosed with a rare malignant germ cell tumour, which affects around one in 200,000 women, Paula drew strength from her athletic background.
She recalled: "When we were over the initial shock and the medical team had explained everything, having that sporting background helped.
"We had a treatment plan - like all the training plans I have followed over the years - and it was something we could stick to and see things improving."
Join the Daily Record WhatsApp community!
Get the latest news sent straight to your messages by joining our WhatsApp community today.
You'll receive daily updates on breaking news as well as the top headlines across Scotland.
No one will be able to see who is signed up and no one can send messages except the Daily Record team.
All you have to do is click here if you're on mobile, select 'Join Community' and you're in!
If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'.
We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like.
To leave our community click on the name at the top of your screen and choose 'exit group'.
Sharing insights into her daughter's ordeal, the marathon legend, 51, confessed: "It's the hardest thing a parent can go through.
"You can support them and be with them the whole way through, but you can't do that chemo for them. It's horrible to watch your child suffering through that, but at the same time, we believed that if it felt bad, it was killing the cancer.
"There are things you're not ready for – either going through it or as a parent."
Ex-Olympian and triple London Marathon champion Paula Radcliffe is set to witness her daughter tackle the same 26.2 mile challenge today, commemorating a decade since Radcliffe said goodbye to marathon running.
Isla will join over 56,000 participants in the 2025 London Marathon on Sunday April 27 in the capital.
Starting at Greenwich Park and culminating on The Mall near Buckingham Palace, runners will follow a mainly flat course passing illustrious landmarks including Tower Bridge, Canary Wharf, and Big Ben.
While Isla has experience in shorter races, this marks her inaugural marathon endeavour. She's running to fundraise for Children with Cancer UK, a charity that resonates deeply with the family following Isla's own battle with the disease.
Paula has shared that her daughter's motivation is to demonstrate her health by completing the marathon, without the aim of breaking any records.
Paula, set to join the BBC commentary team for the event, shared with Radio Times: "It's an extremely emotional place to be anyway, when you see people turn that corner on the Mall and they realise they've done it. But when it's your little girl doing it, that's going to be a bit more emotional."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


NBC News
10 hours ago
- NBC News
FDA grants limited approval to new Covid vaccine from Moderna
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 and older, as well as people ages 12 to 64 with at least one medical condition that increases their risk for severe Covid. The approval, which is limited to individuals who have previously received a Covid vaccine, was granted by the FDA on Friday. Moderna said in a Saturday press release that the new vaccine should be available in the U.S. in time for the 2025-26 respiratory virus season, which starts in the fall. Moderna is also updating its original vaccine to target the LP.8.1 variant this fall. The company submitted an application in May for the FDA to approve the updated formula. The newly approved vaccine, mNEXSPIKE, contains one-fifth of of Moderna's original Covid vaccine dose, Spikevax. It is intended as an alternative for individuals who prefer a lower-dose option, not as a replacement for existing Covid vaccines. But young, healthy adults won't be eligible to receive it, despite their inclusion in Moderna's clinical trial. The FDA imposed similar limitations on Novavax's Covid vaccine when it approved the shot last month. But Friday marks the first time the FDA has greenlit a vaccine since the Trump administration's call for tighter restrictions on vaccine eligibility and approvals. The FDA said last month that it would limit its approval of updated Covid shots moving forward to older adults and younger people with underlying medical conditions. Health and Human Services Secretary Robert F. Kennedy Jr. also announced last week that the Centers for Disease Control and Prevention would no longer recommend Covid vaccines for healthy children and pregnant women. The CDC website appears to soften that recommendation, suggesting that parents can speak with a doctor about vaccinating children 6 months and older. The Trump administration has also said new Covid vaccines must undergo clinical trials with an inert placebo — meaning some participants would receive the new vaccine while others would receive an inactive substance like saline, to compare results. Many new vaccines are tested against older, approved versions, a method considered to be more ethical since using an inert placebo would mean withholding the benefit of a vaccine from study participants. Moderna's new vaccine was tested this way, using what's known as an 'active comparator.' In a trial of around 11,400 participants ages 12 and up, the new vaccine generated higher antibody levels than the company's original Covid shot, according to Moderna. The company also said the new vaccine had fewer local reactions, which typically include redness or swelling at the injection site. Systemic reactions, which may include fever, headaches or chills, were comparable between the shots. The main side effects of mNEXSPIKE were injection site pain, fatigue, headache and muscle pain, Moderna said in its press release.


Channel 4
12 hours ago
- Channel 4
Israel-backed aid organisation denying attack in Gaza ‘nonsense' says surgeon
We spoke to Graeme Groom, a British surgeon currently working at Nasser Hospital in Gaza. He worked alongside Dr Hamdi al-Najjar, who today succumbed to his injuries from last week's air strike that killed nine of his ten children. We asked him what his understanding of the situation is, following the reported Israeli attacks on civilians near an aid distribution centre.


Channel 4
14 hours ago
- Channel 4
Israel denying aid site attack in Gaza ‘nonsense' says surgeon
We spoke to Graeme Groom, a British surgeon currently working at Nasser Hospital in Gaza. He worked alongside Dr Hamdi al-Najjar, who today succumbed to his injuries from last week's air strike that killed nine of his ten children. We asked him what his understanding of the situation is, following the reported Israeli attacks on civilians near an aid distribution centre.